

30 September 2024

ASX Announcement

## Notice of Annual General Meeting and Closing Date for Director Nominations

---

**Firebrick Pharma Limited** (ASX: FRE) (**Company** or **Firebrick**) advises that the Company's Annual General Meeting (**AGM**) is scheduled to be convened at 3.00pm (AEDT) on Wednesday, 27 November 2024.

The AGM will be held as a virtual meeting through an online meeting platform powered by Automic, where Shareholders will be able to watch, listen, and vote online.

In accordance with the Company's Constitution, the closing date for receipt of director nominations to the Company from persons wishing to be considered for election as a director, is Wednesday, 9 October 2024. Any nominations must be received in writing at the Company's registered office by 5.00pm (AEST).

The AGM materials will be produced and provided to shareholders in due course.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

### About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has successfully developed a PVP-I nasal spray (Nasodine® Nasal Spray) and filed international trademarks and multiple patents on the product. The Company has also completed six clinical trials that have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Firebrick is now commercialising Nasodine in international markets, with the product already launched in the United States and Singapore.

#### Media enquiries:

Heidi Cuthbert  
+61 411 272 366  
[heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)

#### Investor enquiries:

[Investors@firebrickpharma.com](mailto:Investors@firebrickpharma.com)